

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Fusen Pharmaceutical Company Limited

福森藥業有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1652)

NOTICE OF BOARD MEETING AND DELAY IN DESPATCH OF 2019 ANNUAL REPORT

References are made to the announcement of Fusen Pharmaceutical Company Limited (the “**Company**”) dated 31 March 2020 in relation to the meeting of the board of directors (the “**Board**”) of the Company held on 31 March 2020, and the unaudited annual results announcement of the Company and its subsidiaries (the “**Group**”) for the year ended 31 December 2019 (the “**Announcement**”) dated 31 March 2020.

The Board hereby announces that a meeting of the Board will be held on Wednesday, 6 May 2020 for purpose of, among other matters, considering and approving the audited annual results of the Group for the year ended 31 December 2019, and its publication.

As disclosed in the Announcement, due to restrictions in force in parts of China to combat the outbreak of COVID-19, the audit of the financial statements of the Group for the year ended 31 December 2019 has been affected. The publication and despatch of the annual report for the year ended 31 December 2019 (the “**Annual Report**”) will hence be delayed and the Company will not be able to despatch the Annual Report on or before 30 April 2020 according to Rule 13.46(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”). However, in accordance with the FURTHER GUIDANCE ON THE JOINT STATEMENT IN RELATION TO RESULTS ANNOUNCEMENTS IN LIGHT OF THE COVID-19 PANDEMIC released on 16 March 2020 (“**Further Guidance**”) by The Securities and Futures Commission and the Stock Exchange, an issuer may defer the publication of the annual report initially for up to 60 days from the date of the Further Guidance if, among other things, on or before 31 March 2020, the issuer has published its preliminary results without its auditors’ agreement pursuant to

the relevant joint statement released on 4 February 2020. Taking into account of the progress of the preparation of the audited annual results and the Annual Report, the Company expects to despatch the Annual Report to the shareholders of the Company on or before 15 May 2020.

By order of the Board
Fusen Pharmaceutical Company Limited
Cao Changcheng
Chairman and Executive Director

Hong Kong, 20 April 2020

As at the date of this announcement, the Board of the Company comprises Mr. Cao Changcheng (Chairman), Mr. Hou Taisheng, Mr. Chi Yongsheng, Ms. Meng Qingfen and Mr. Cao Zhiming (formerly known as Mr. Cao Dudu) as executive Directors, and Mr. Sze Wing Chun, Mr. Lee Kwok Tung, Louis and Mr. Ho Ka Chun as independent non-executive Directors.